Navigation Links
Children's National researcher receives ACCP Distinguished Investigator Award
Date:9/8/2008

The American College of Clinical Pharmacology (ACCP) has awarded John van den Anker, MD, PhD, director of Pediatric Clinical Pharmacology at Children's National Medical Center, its annual Distinguished Investigator Award.

Dr. van den Anker, a neonatologist by training, receives this award for "his sustained and prolific contributions to pediatric clinical pharmacology," according to the ACCP.

The Distinguished Investigator Award is given yearly and recognizes superior scientific expertise and accomplishments by a senior investigator, usually involving a distinct area of research in basic or clinical pharmacology for which the individual is internationally known.

Dr. van den Anker is the director of Pediatric Clinical Pharmacology at Children's National Medical Center, and also serves as associate director of Children's Research Institute's Center for Clinical and Community Research. He is professor of Pediatrics, Pharmacology, and Physiology at the George Washington University School of Medicine and Health Sciences, and holds the Evan and Cindy Jones Chair in Pediatric Clinical Pharmacology at Children's National. He has received several major awards from the National Institutes of Health and has published more than 150 peer reviewed papers in the field of neonatal and pediatric clinical pharmacology. He also served as the president of the European Society of Developmental, Perinatal, and Pediatric Pharmacology from 2006-2008.


'/>"/>

Contact: Jennifer Leischer
jleische@cnmc.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Page: 1

Related biology news :

1. Corporate Safe Specialists Launches International Sales Efforts
2. New chemical radar among national security innovations in ACS podcast
3. International team reveals first prognosticator of survival in aggressive cancer
4. White House announces 2007 National Medal of Science laureates
5. National security remedies among topics at surveillance confab
6. Duke Medicine physician-scientist receives National Medal of Science
7. National Research Council report on security at federally managed dams
8. Food, health get top billing at national chemistry meeting
9. Childrens national co-leads nationwide study of landmark sickle cell treatment
10. Story tips from the US Department of Energys Oak Ridge National Laboratory, August 2008
11. [video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.nets 3-Minute Press Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... , Feb. 20, 2017  Atrius Health and ... entered into an agreement to develop a cloud ... By providing a holistic view of the multiple ... Watson Cognitive Insights could be designed to support ... Health is an innovative nonprofit healthcare organization with ...
(Date:2/18/2017)... Feb 17, 2017 Research and Markets has ... Report" report to their offering. ... The report provides separate comprehensive analytics for ... , and Rest of World. Annual estimates and forecasts are provided ... is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today presented ... drug candidates, PTG-100 and PTG-200, at the 12 ... Colitis Organization (ECCO).  The ECCO congress is being ... from February 15 – 18, 2017. ... drug candidates PTG-100 and PTG-200. PTG-100, a potential ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
Breaking Biology Technology: